F&FFinancial Insights

Financial Metrics

LH LABCORP HOLDINGS INC.
Range: 2016-01-01 to 2026-04-29
Export Quarterly CSV Export Annual CSV
Chart Range:
% Change:

Financial Statements

Grouped by statement

Income Statement

Metrics: 6

Revenue

Q: 30 | A: 10

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2016-03-31 2295200000.0 — USD 10-Q 2017-04-28
Quarterly 2016-06-30 2382000000.0 +3.8% USD 10-Q 2017-08-02
Quarterly 2016-09-30 2372700000.0 -0.4% USD 10-Q 2017-11-02
Quarterly 2017-03-31 2413700000.0 +1.7% USD 10-Q 2018-05-01
Quarterly 2017-06-30 2528200000.0 +4.7% USD 10-Q 2018-07-27
Quarterly 2017-09-30 2621400000.0 +3.7% USD 10-Q 2018-10-30
Quarterly 2018-03-31 2848300000.0 +8.7% USD 10-Q 2019-05-03
Quarterly 2018-06-30 2866300000.0 +0.6% USD 10-Q 2019-08-08
Quarterly 2018-09-30 2831300000.0 -1.2% USD 10-Q 2019-10-31
Quarterly 2019-03-31 2791200000.0 -1.4% USD 10-Q 2020-05-08
Quarterly 2019-06-30 2881700000.0 +3.2% USD 10-Q 2020-07-31
Quarterly 2019-09-30 2928500000.0 +1.6% USD 10-Q 2020-10-29
Quarterly 2020-03-31 2823800000.0 -3.6% USD 10-Q 2021-05-04
Quarterly 2020-06-30 2768800000.0 -1.9% USD 10-Q 2021-08-05
Quarterly 2020-09-30 3896100000.0 +40.7% USD 10-Q 2021-11-02
Quarterly 2021-03-31 4161500000.0 +6.8% USD 10-Q 2022-04-29
Quarterly 2021-06-30 3840700000.0 -7.7% USD 10-Q 2022-08-01
Quarterly 2021-09-30 4062600000.0 +5.8% USD 10-Q 2022-11-01
Quarterly 2022-03-31 3899600000.0 -4.0% USD 10-Q 2023-05-04
Quarterly 2022-06-30 2923000000.0 -25.0% USD 10-Q 2023-08-04
Quarterly 2022-09-30 2866800000.0 -1.9% USD 10-Q 2023-10-30
Quarterly 2023-03-31 3037800000.0 +6.0% USD 10-Q 2024-04-30
Quarterly 2023-06-30 3033700000.0 -0.1% USD 10-Q 2024-08-02
Quarterly 2023-09-30 3056800000.0 +0.8% USD 10-Q 2024-10-29
Quarterly 2024-03-31 3176600000.0 +3.9% USD 10-Q 2025-04-29
Quarterly 2024-06-30 3220900000.0 +1.4% USD 10-Q 2025-08-01
Quarterly 2024-09-30 3282000000.0 +1.9% USD 10-Q 2025-10-31
Quarterly 2025-03-31 3345100000.0 +1.9% USD 10-Q 2025-04-29
Quarterly 2025-06-30 3527300000.0 +5.4% USD 10-Q 2025-08-01
Quarterly 2025-09-30 3563500000.0 +1.0% USD 10-Q 2025-10-31
Annual 2016-12-31 9552900000.0 — USD 10-K 2019-02-28
Annual 2017-12-31 10308000000.0 +7.9% USD 10-K 2020-02-28
Annual 2018-12-31 11333400000.0 +9.9% USD 10-K 2021-02-25
Annual 2019-12-31 11554800000.0 +2.0% USD 10-K 2022-02-25
Annual 2020-12-31 13978500000.0 +21.0% USD 10-K 2023-02-28
Annual 2021-12-31 13136100000.0 -6.0% USD 10-K 2024-02-26
Annual 2022-12-31 11863900000.0 -9.7% USD 10-K 2025-02-25
Annual 2023-12-31 12161600000.0 +2.5% USD 10-K 2026-02-24
Annual 2024-12-31 13008900000.0 +7.0% USD 10-K 2026-02-24
Annual 2025-12-31 13951700000.0 +7.2% USD 10-K 2026-02-24

Gross Profit

Q: 30 | A: 10

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2016-03-31 777300000.0 — USD 10-Q 2017-04-28
Quarterly 2016-06-30 826800000.0 +6.4% USD 10-Q 2017-08-02
Quarterly 2016-09-30 788400000.0 -4.6% USD 10-Q 2017-11-02
Quarterly 2017-03-31 712500000.0 -9.6% USD 10-Q 2018-05-01
Quarterly 2017-06-30 778000000.0 +9.2% USD 10-Q 2018-07-27
Quarterly 2017-09-30 784200000.0 +0.8% USD 10-Q 2018-10-30
Quarterly 2018-03-31 779000000.0 -0.7% USD 10-Q 2019-05-03
Quarterly 2018-06-30 835100000.0 +7.2% USD 10-Q 2019-08-08
Quarterly 2018-09-30 789900000.0 -5.4% USD 10-Q 2019-10-31
Quarterly 2019-03-31 789700000.0 -0.0% USD 10-Q 2020-05-08
Quarterly 2019-06-30 824800000.0 +4.4% USD 10-Q 2020-07-31
Quarterly 2019-09-30 817300000.0 -0.9% USD 10-Q 2020-10-29
Quarterly 2020-03-31 728000000.0 -10.9% USD 10-Q 2021-05-04
Quarterly 2020-06-30 760500000.0 +4.5% USD 10-Q 2021-08-05
Quarterly 2020-09-30 1559400000.0 +105.0% USD 10-Q 2021-11-02
Quarterly 2021-03-31 1599000000.0 +2.5% USD 10-Q 2022-04-29
Quarterly 2021-06-30 1264800000.0 -20.9% USD 10-Q 2022-08-01
Quarterly 2021-09-30 1385500000.0 +9.5% USD 10-Q 2022-11-01
Quarterly 2022-03-31 1232900000.0 -11.0% USD 10-Q 2023-05-04
Quarterly 2022-06-30 942500000.0 -23.6% USD 10-Q 2023-08-04
Quarterly 2022-09-30 886200000.0 -6.0% USD 10-Q 2023-10-30
Quarterly 2023-03-31 850100000.0 -4.1% USD 10-Q 2024-04-30
Quarterly 2023-06-30 842200000.0 -0.9% USD 10-Q 2024-08-02
Quarterly 2023-09-30 851200000.0 +1.1% USD 10-Q 2024-10-29
Quarterly 2024-03-31 897300000.0 +5.4% USD 10-Q 2025-04-29
Quarterly 2024-06-30 926400000.0 +3.2% USD 10-Q 2025-08-01
Quarterly 2024-09-30 904400000.0 -2.4% USD 10-Q 2025-10-31
Quarterly 2025-03-31 948000000.0 +4.8% USD 10-Q 2025-04-29
Quarterly 2025-06-30 1046200000.0 +10.4% USD 10-Q 2025-08-01
Quarterly 2025-09-30 1025100000.0 -2.0% USD 10-Q 2025-10-31
Annual 2016-12-31 2854000000.0 — USD 10-K 2019-02-28
Annual 2017-12-31 3091800000.0 +8.3% USD 10-K 2020-02-28
Annual 2018-12-31 3176400000.0 +2.7% USD 10-K 2021-02-25
Annual 2019-12-31 3252500000.0 +2.4% USD 10-K 2022-02-25
Annual 2020-12-31 4952800000.0 +52.3% USD 10-K 2023-02-28
Annual 2021-12-31 4992400000.0 +0.8% USD 10-K 2024-02-26
Annual 2022-12-31 3708900000.0 -25.7% USD 10-K 2025-02-25
Annual 2023-12-31 3364900000.0 -9.3% USD 10-K 2026-02-24
Annual 2024-12-31 3624400000.0 +7.7% USD 10-K 2026-02-24
Annual 2025-12-31 4012500000.0 +10.7% USD 10-K 2026-02-24

Operating Income

Q: 30 | A: 10

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2016-03-31 299500000.0 — USD 10-Q 2017-04-28
Quarterly 2016-06-30 365500000.0 +22.0% USD 10-Q 2017-08-02
Quarterly 2016-09-30 324000000.0 -11.4% USD 10-Q 2017-11-02
Quarterly 2017-03-31 318100000.0 -1.8% USD 10-Q 2018-05-01
Quarterly 2017-06-30 329800000.0 +3.7% USD 10-Q 2018-07-27
Quarterly 2017-09-30 326700000.0 -0.9% USD 10-Q 2018-10-30
Quarterly 2018-03-31 305400000.0 -6.5% USD 10-Q 2019-05-03
Quarterly 2018-06-30 369200000.0 +20.9% USD 10-Q 2019-08-08
Quarterly 2018-09-30 343400000.0 -7.0% USD 10-Q 2019-10-31
Quarterly 2019-03-31 318200000.0 -7.3% USD 10-Q 2020-05-08
Quarterly 2019-06-30 335700000.0 +5.5% USD 10-Q 2020-07-31
Quarterly 2019-09-30 339900000.0 +1.3% USD 10-Q 2020-10-29
Quarterly 2020-03-31 -192600000.0 -156.7% USD 10-Q 2021-05-04
Quarterly 2020-06-30 297700000.0 +254.6% USD 10-Q 2021-08-05
Quarterly 2020-09-30 1047100000.0 +251.7% USD 10-Q 2021-11-02
Quarterly 2021-03-31 1057900000.0 +1.0% USD 10-Q 2022-04-29
Quarterly 2021-06-30 704100000.0 -33.4% USD 10-Q 2022-08-01
Quarterly 2021-09-30 766900000.0 +8.9% USD 10-Q 2022-11-01
Quarterly 2022-03-31 687900000.0 -10.3% USD 10-Q 2023-05-04
Quarterly 2022-06-30 428800000.0 -37.7% USD 10-Q 2023-08-04
Quarterly 2022-09-30 374000000.0 -12.8% USD 10-Q 2023-10-30
Quarterly 2023-03-31 329800000.0 -11.8% USD 10-Q 2024-04-30
Quarterly 2023-06-30 266300000.0 -19.3% USD 10-Q 2024-08-02
Quarterly 2023-09-30 252300000.0 -5.3% USD 10-Q 2024-10-29
Quarterly 2024-03-31 321300000.0 +27.3% USD 10-Q 2025-04-29
Quarterly 2024-06-30 294800000.0 -8.2% USD 10-Q 2025-08-01
Quarterly 2024-09-30 254100000.0 -13.8% USD 10-Q 2025-10-31
Quarterly 2025-03-31 326000000.0 +28.3% USD 10-Q 2025-04-29
Quarterly 2025-06-30 394500000.0 +21.0% USD 10-Q 2025-08-01
Quarterly 2025-09-30 396600000.0 +0.5% USD 10-Q 2025-10-31
Annual 2016-12-31 1270600000.0 — USD 10-K 2019-02-28
Annual 2017-12-31 1305200000.0 +2.7% USD 10-K 2020-02-28
Annual 2018-12-31 1325700000.0 +1.6% USD 10-K 2021-02-25
Annual 2019-12-31 1330200000.0 +0.3% USD 10-K 2022-02-25
Annual 2020-12-31 2445400000.0 +83.8% USD 10-K 2023-02-28
Annual 2021-12-31 3048600000.0 +24.7% USD 10-K 2024-02-26
Annual 2022-12-31 1436500000.0 -52.9% USD 10-K 2025-02-25
Annual 2023-12-31 725600000.0 -49.5% USD 10-K 2026-02-24
Annual 2024-12-31 1086700000.0 +49.8% USD 10-K 2026-02-24
Annual 2025-12-31 1384700000.0 +27.4% USD 10-K 2026-02-24

Net Income

Q: 30 | A: 10

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2016-03-31 164400000.0 — USD 10-Q 2017-04-28
Quarterly 2016-06-30 204400000.0 +24.3% USD 10-Q 2017-08-02
Quarterly 2016-09-30 179800000.0 -12.0% USD 10-Q 2017-11-02
Quarterly 2017-03-31 183300000.0 +1.9% USD 10-Q 2018-05-01
Quarterly 2017-06-30 185100000.0 +1.0% USD 10-Q 2018-07-27
Quarterly 2017-09-30 174300000.0 -5.8% USD 10-Q 2018-10-30
Quarterly 2018-03-31 173200000.0 -0.6% USD 10-Q 2019-10-31
Quarterly 2018-06-30 233800000.0 +35.0% USD 10-Q 2019-10-31
Quarterly 2018-09-30 319000000.0 +36.4% USD 10-Q 2019-10-31
Quarterly 2019-03-31 185600000.0 -41.8% USD 10-Q 2020-10-29
Quarterly 2019-06-30 190400000.0 +2.6% USD 10-Q 2020-10-29
Quarterly 2019-09-30 -317200000.0 -266.6% USD 10-Q 2021-05-04
Quarterly 2020-03-31 -317200000.0 +0.0% USD 10-Q 2021-11-02
Quarterly 2020-06-30 231600000.0 +173.0% USD 10-Q 2021-11-02
Quarterly 2020-09-30 703700000.0 +203.8% USD 10-Q 2021-11-02
Quarterly 2021-03-31 769600000.0 +9.4% USD 10-Q 2022-11-01
Quarterly 2021-06-30 467400000.0 -39.3% USD 10-Q 2022-11-01
Quarterly 2021-09-30 587800000.0 +25.8% USD 10-Q 2022-11-01
Quarterly 2022-03-31 491600000.0 -16.4% USD 10-Q 2023-10-30
Quarterly 2022-06-30 358600000.0 -27.1% USD 10-Q 2023-10-30
Quarterly 2022-09-30 353200000.0 -1.5% USD 10-Q 2023-10-30
Quarterly 2023-03-31 212900000.0 -39.7% USD 10-Q 2024-10-29
Quarterly 2023-06-30 188900000.0 -11.3% USD 10-Q 2024-10-29
Quarterly 2023-09-30 183600000.0 -2.8% USD 10-Q 2024-10-29
Quarterly 2024-03-31 228000000.0 +24.2% USD 10-Q 2025-10-31
Quarterly 2024-06-30 205300000.0 -10.0% USD 10-Q 2025-10-31
Quarterly 2024-09-30 169600000.0 -17.4% USD 10-Q 2025-10-31
Quarterly 2025-03-31 212800000.0 +25.5% USD 10-Q 2025-10-31
Quarterly 2025-06-30 237900000.0 +11.8% USD 10-Q 2025-10-31
Quarterly 2025-09-30 261500000.0 +9.9% USD 10-Q 2025-10-31
Annual 2016-12-31 712900000.0 — USD 10-K 2019-02-28
Annual 2017-12-31 1232900000.0 +72.9% USD 10-K 2020-02-28
Annual 2018-12-31 883900000.0 -28.3% USD 10-K 2021-02-25
Annual 2019-12-31 824900000.0 -6.7% USD 10-K 2022-02-25
Annual 2020-12-31 1557000000.0 +88.8% USD 10-K 2023-02-28
Annual 2021-12-31 2379500000.0 +52.8% USD 10-K 2024-02-26
Annual 2022-12-31 1280600000.0 -46.2% USD 10-K 2025-02-25
Annual 2023-12-31 419200000.0 -67.3% USD 10-K 2026-02-24
Annual 2024-12-31 747100000.0 +78.2% USD 10-K 2026-02-24
Annual 2025-12-31 877700000.0 +17.5% USD 10-K 2026-02-24

EPS Basic

Q: 30 | A: 10

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2016-03-31 1.61 — USD/shares 10-Q 2017-04-28
Quarterly 2016-06-30 2.0 +24.2% USD/shares 10-Q 2017-08-02
Quarterly 2016-09-30 1.74 -13.0% USD/shares 10-Q 2017-11-02
Quarterly 2017-03-31 1.79 +2.9% USD/shares 10-Q 2018-05-01
Quarterly 2017-06-30 1.8 +0.6% USD/shares 10-Q 2018-07-27
Quarterly 2017-09-30 1.68 -6.7% USD/shares 10-Q 2018-10-30
Quarterly 2018-03-31 1.7 +1.2% USD/shares 10-Q 2019-05-03
Quarterly 2018-06-30 2.29 +34.7% USD/shares 10-Q 2019-08-08
Quarterly 2018-09-30 3.14 +37.1% USD/shares 10-Q 2019-10-31
Quarterly 2019-03-31 1.88 -40.1% USD/shares 10-Q 2020-05-08
Quarterly 2019-06-30 1.94 +3.2% USD/shares 10-Q 2020-07-31
Quarterly 2019-09-30 2.26 +16.5% USD/shares 10-Q 2020-10-29
Quarterly 2020-03-31 -3.27 -244.7% USD/shares 10-Q 2021-05-04
Quarterly 2020-06-30 2.38 +172.8% USD/shares 10-Q 2021-08-05
Quarterly 2020-09-30 7.22 +203.4% USD/shares 10-Q 2021-11-02
Quarterly 2021-03-31 7.88 +9.1% USD/shares 10-Q 2022-04-29
Quarterly 2021-06-30 4.8 -39.1% USD/shares 10-Q 2022-08-01
Quarterly 2021-09-30 6.1 +27.1% USD/shares 10-Q 2022-11-01
Quarterly 2022-03-31 5.27 -13.6% USD/shares 10-Q 2023-05-04
Quarterly 2022-06-30 3.89 -26.2% USD/shares 10-Q 2023-08-04
Quarterly 2022-09-30 3.91 +0.5% USD/shares 10-Q 2023-10-30
Quarterly 2023-03-31 2.41 -38.4% USD/shares 10-Q 2024-04-30
Quarterly 2023-06-30 2.13 -11.6% USD/shares 10-Q 2024-08-02
Quarterly 2023-09-30 2.12 -0.5% USD/shares 10-Q 2024-10-29
Quarterly 2024-03-31 2.71 +27.8% USD/shares 10-Q 2025-04-29
Quarterly 2024-06-30 2.44 -10.0% USD/shares 10-Q 2025-08-01
Quarterly 2024-09-30 2.02 -17.2% USD/shares 10-Q 2025-10-31
Quarterly 2025-03-31 2.54 +25.7% USD/shares 10-Q 2025-04-29
Quarterly 2025-06-30 2.85 +12.2% USD/shares 10-Q 2025-08-01
Quarterly 2025-09-30 3.14 +10.2% USD/shares 10-Q 2025-10-31
Annual 2016-12-31 6.94 — USD/shares 10-K 2019-02-28
Annual 2017-12-31 11.99 +72.8% USD/shares 10-K 2020-02-28
Annual 2018-12-31 8.71 -27.4% USD/shares 10-K 2021-02-25
Annual 2019-12-31 8.42 -3.3% USD/shares 10-K 2022-02-25
Annual 2020-12-31 15.99 +89.9% USD/shares 10-K 2023-02-28
Annual 2021-12-31 24.6 +53.8% USD/shares 10-K 2024-02-26
Annual 2022-12-31 14.05 -42.9% USD/shares 10-K 2025-02-25
Annual 2023-12-31 4.8 -65.8% USD/shares 10-K 2026-02-24
Annual 2024-12-31 8.89 +85.2% USD/shares 10-K 2026-02-24
Annual 2025-12-31 10.54 +18.6% USD/shares 10-K 2026-02-24

EPS Diluted

Q: 30 | A: 10

Quarterly

Annual

Show Data Rows
Frequency Period End Value % Chg Unit Form Filed
Quarterly 2016-03-31 1.58 — USD/shares 10-Q 2017-04-28
Quarterly 2016-06-30 1.96 +24.1% USD/shares 10-Q 2017-08-02
Quarterly 2016-09-30 1.71 -12.8% USD/shares 10-Q 2017-11-02
Quarterly 2017-03-31 1.75 +2.3% USD/shares 10-Q 2018-05-01
Quarterly 2017-06-30 1.78 +1.7% USD/shares 10-Q 2018-07-27
Quarterly 2017-09-30 1.65 -7.3% USD/shares 10-Q 2018-10-30
Quarterly 2018-03-31 1.67 +1.2% USD/shares 10-Q 2019-05-03
Quarterly 2018-06-30 2.27 +35.9% USD/shares 10-Q 2019-08-08
Quarterly 2018-09-30 3.1 +36.6% USD/shares 10-Q 2019-10-31
Quarterly 2019-03-31 1.86 -40.0% USD/shares 10-Q 2020-05-08
Quarterly 2019-06-30 1.93 +3.8% USD/shares 10-Q 2020-07-31
Quarterly 2019-09-30 2.25 +16.6% USD/shares 10-Q 2020-10-29
Quarterly 2020-03-31 -3.27 -245.3% USD/shares 10-Q 2021-05-04
Quarterly 2020-06-30 2.37 +172.5% USD/shares 10-Q 2021-08-05
Quarterly 2020-09-30 7.17 +202.5% USD/shares 10-Q 2021-11-02
Quarterly 2021-03-31 7.82 +9.1% USD/shares 10-Q 2022-04-29
Quarterly 2021-06-30 4.76 -39.1% USD/shares 10-Q 2022-08-01
Quarterly 2021-09-30 6.05 +27.1% USD/shares 10-Q 2022-11-01
Quarterly 2022-03-31 5.23 -13.6% USD/shares 10-Q 2023-05-04
Quarterly 2022-06-30 3.87 -26.0% USD/shares 10-Q 2023-08-04
Quarterly 2022-09-30 3.9 +0.8% USD/shares 10-Q 2023-10-30
Quarterly 2023-03-31 2.39 -38.7% USD/shares 10-Q 2024-04-30
Quarterly 2023-06-30 2.12 -11.3% USD/shares 10-Q 2024-08-02
Quarterly 2023-09-30 2.11 -0.5% USD/shares 10-Q 2024-10-29
Quarterly 2024-03-31 2.69 +27.5% USD/shares 10-Q 2025-04-29
Quarterly 2024-06-30 2.43 -9.7% USD/shares 10-Q 2025-08-01
Quarterly 2024-09-30 2.0 -17.7% USD/shares 10-Q 2025-10-31
Quarterly 2025-03-31 2.52 +26.0% USD/shares 10-Q 2025-04-29
Quarterly 2025-06-30 2.84 +12.7% USD/shares 10-Q 2025-08-01
Quarterly 2025-09-30 3.12 +9.9% USD/shares 10-Q 2025-10-31
Annual 2016-12-31 6.82 — USD/shares 10-K 2019-02-28
Annual 2017-12-31 11.81 +73.2% USD/shares 10-K 2020-02-28
Annual 2018-12-31 8.61 -27.1% USD/shares 10-K 2021-02-25
Annual 2019-12-31 8.35 -3.0% USD/shares 10-K 2022-02-25
Annual 2020-12-31 15.88 +90.2% USD/shares 10-K 2023-02-28
Annual 2021-12-31 24.39 +53.6% USD/shares 10-K 2024-02-26
Annual 2022-12-31 13.97 -42.7% USD/shares 10-K 2025-02-25
Annual 2023-12-31 4.77 -65.9% USD/shares 10-K 2026-02-24
Annual 2024-12-31 8.84 +85.3% USD/shares 10-K 2026-02-24
Annual 2025-12-31 10.46 +18.3% USD/shares 10-K 2026-02-24

8-K Material Event Details

120 filings · 242 item records

This 8-K section tracks corporate event disclosures, not insider buy/sell sentiment. Insider trading direction is shown in the insider section below.

Event Type Distribution

Count per 8-K item

Insider Transaction History

367 transaction records

Net Insider Flow

Monthly open-market buy value minus open-market sell value

Monthly Insider Activity Mix

Share volume split between open-market trades, grants, and exercises

Transaction Value Timeline

Each circle = one priced transaction; size ∝ value

All Transactions

Date Insider Title Type Security Shares Price Total Value Post-Tx Shares
2026-03-26 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 26,106 $268.38 $7,006,328 113,137
2026-03-26 Schechter Adam H President & CEO Equity grant / award
A
 Common Stock 58,470 $0.00 $0 139,243
2026-03-03 Schechter Adam H President & CEO Open-market sell
S
 Common Stock 8,705 $279.96 $2,437,047 80,773
2026-02-27 van der Vaart Sandra D EVP, Corporate Affairs Open-market sell
S
 Common Stock 548 $284.91 $156,000 2,579
2026-02-24 Caveney Brian J EVP, Pres of ED, CMO & CSO Open-market sell
S
 Common Stock 1,500 $286.31 $429,458 30,107
2026-02-19 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 666 $277.94 $185,108 1,852
2026-02-11 Summy Amy B. EVP, Chief Marketing Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 230 $0.00 $0 1,304
2026-02-11 Summy Amy B. EVP, Chief Marketing Officer Other disposed transaction
F
 Common Stock 83 $289.89 $24,061 5,722
2026-02-11 Summy Amy B. EVP, Chief Marketing Officer Exercise / conversion
M
 Common Stock 230 — — 5,804
2026-02-10 Schechter Adam H President & CEO Equity grant / award
A · derivative
 Restricted Stock Unit 10,440 $0.00 $0 25,870
2026-02-10 Schechter Adam H President & CEO Equity grant / award
A · derivative
 Non-qualified Stock Options 31,700 $0.00 $0 31,700
2026-02-06 Wang Julia Aijun Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Restricted Stock Unit 893 $0.00 $0 3,474
2026-02-06 Wang Julia Aijun Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 254 $277.20 $70,409 1,202
2026-02-06 Wang Julia Aijun Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 893 — — 1,456
2025-12-01 Bulto Carulla Victor Dir Equity grant / award
A · derivative
 Restricted Stock Unit 136 $0.00 $0 136
2025-11-11 Schechter Adam H President & CEO Open-market sell
S
 Common Stock 5,745 $262.75 $1,509,499 87,574
2025-11-03 Bailey Megan D. EVP, Pres, Central Labs & Intl Other disposed transaction
F
 Common Stock 179 $257.84 $46,153 3,594
2025-11-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Exercise / conversion
M · derivative
 Restricted Stock Unit 370 $0.00 $0 2,599
2025-11-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Exercise / conversion
M
 Common Stock 370 — — 3,773
2025-10-31 Parham Richelle P Dir Open-market sell
S
 Common Stock 7,009 $254.28 $1,782,273 2,469
2025-08-13 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,903 $0.00 $0 0
2025-08-13 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 3,903 $271.42 $1,059,371 2,274
2025-08-13 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M
 Common Stock 3,903 $131.43 $512,971 6,177
2025-08-11 Schechter Adam H President & CEO Open-market sell
S
 Common Stock 5,643 $266.78 $1,505,440 93,319
2025-07-30 Gilliland Dwight Gary Dir Open-market sell
S
 Common Stock 2,000 $264.95 $529,900 6,656
2025-07-29 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 100 $261.04 $26,104 1,852
2025-07-29 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 102 $261.01 $26,623 1,952
2025-07-24 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 3,500 $280.00 $980,000 8,666
2025-07-01 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 500 $265.00 $132,500 12,166
2025-06-11 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 500 $260.00 $130,000 12,666
2025-06-03 Caveney Brian J EVP, Pres of ED, CMO & CSO Open-market sell
S
 Common Stock 2,000 $247.00 $494,000 30,067
2025-05-12 Schechter Adam H President & CEO Open-market sell
S
 Common Stock 6,105 $248.73 $1,518,497 98,962
2025-05-01 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 1,900 $238.36 $452,884 2,244
2025-04-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Exercise / conversion
M · derivative
 Restricted Stock Unit 204 $0.00 $0 2,969
2025-04-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Exercise / conversion
M · derivative
 Restricted Stock Unit 4,083 $0.00 $0 3,173
2025-04-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Other disposed transaction
F
 Common Stock 68 $232.65 $15,820 3,403
2025-04-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Exercise / conversion
M
 Common Stock 204 — — 3,471
2025-04-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Other disposed transaction
F
 Common Stock 1,546 $232.65 $359,677 3,267
2025-04-01 Bailey Megan D. EVP, Pres, Central Labs & Intl Exercise / conversion
M
 Common Stock 4,083 — — 4,813
2025-03-28 Summy Amy B. EVP, Chief Marketing Officer Open-market sell
S
 Common Stock 758 $231.67 $175,606 5,302
2025-03-27 Summy Amy B. EVP, Chief Marketing Officer Other disposed transaction
F
 Common Stock 562 $231.67 $130,199 6,060
2025-03-27 Summy Amy B. EVP, Chief Marketing Officer Equity grant / award
A
 Common Stock 2,077 $0.00 $0 6,622
2025-03-05 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 500 $255.63 $127,817 13,166
2025-02-28 Schroeder Mark S EVP, Pres Diagnostics & COO Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,903 $0.00 $0 0
2025-02-28 Schroeder Mark S EVP, Pres Diagnostics & COO Open-market sell
S
 Common Stock 5,339 $249.23 $1,330,639 4,960
2025-02-28 Schroeder Mark S EVP, Pres Diagnostics & COO Exercise / conversion
M
 Common Stock 3,903 $131.43 $512,971 10,299
2025-02-25 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 1,314 $251.30 $330,208 2,171
2025-02-24 Summy Amy B. EVP, Chief Marketing Officer Open-market sell
S
 Common Stock 226 $250.40 $56,590 4,544
2025-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 1,413 $0.00 $0 0
2025-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 1,413 $246.10 $347,739 1,993
2025-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 1,413 $163.63 $231,209 3,406
2025-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 123 $0.00 $0 2,491
2025-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Restricted Stock Unit 1,610 $0.00 $0 2,614
2025-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Restricted Stock Unit 480 $0.00 $0 1,004
2025-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Non-qualified Stock Options 1,500 $0.00 $0 1,500
2025-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 41 $245.14 $10,051 2,344
2025-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 123 — — 2,385
2025-02-07 EISENBERG GLENN A Executive Vice President Exercise / conversion
M · derivative
 Restricted Stock Unit 885 $0.00 $0 3,626
2025-02-07 EISENBERG GLENN A Executive Vice President Other disposed transaction
F
 Common Stock 234 $246.27 $57,627 32,651
2025-02-07 EISENBERG GLENN A Executive Vice President Exercise / conversion
M
 Common Stock 885 — — 32,885
2025-02-06 EISENBERG GLENN A Executive Vice President Exercise / conversion
M · derivative
 Restricted Stock Unit 966 $0.00 $0 4,511
2025-02-06 EISENBERG GLENN A Executive Vice President Other disposed transaction
F
 Common Stock 255 $247.74 $63,174 32,000
2025-02-06 EISENBERG GLENN A Executive Vice President Exercise / conversion
M
 Common Stock 966 — — 32,255
2025-01-07 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 1,000 $235.00 $235,000 12,722
2024-12-02 Wang Julia Aijun Chief Financial Officer, EVP Equity grant / award
A · derivative
 Restricted Stock Unit 2,680 $0.00 $0 2,680
2024-12-02 Wang Julia Aijun Chief Financial Officer, EVP Equity grant / award
A · derivative
 Non-qualified Stock Options 8,100 $0.00 $0 8,100
2024-11-22 Summy Amy B. EVP, Chief Marketing Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 4,015 $0.00 $0 0
2024-11-22 Summy Amy B. EVP, Chief Marketing Officer Open-market sell
S
 Common Stock 3,672 $238.91 $877,142 4,318
2024-11-22 Summy Amy B. EVP, Chief Marketing Officer Exercise / conversion
M
 Common Stock 4,015 $168.52 $676,608 7,990
2024-11-21 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 1,000 $239.42 $239,419 2,670
2024-11-11 Schechter Adam H President & CEO Open-market sell
S
 Common Stock 6,189 $243.47 $1,506,836 87,441
2024-11-01 Oyegunwa Akinbolade EVP, CIO & CTO Equity grant / award
A · derivative
 Restricted Stock Unit 1,110 $0.00 $0 2,082
2024-10-24 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 1,000 $230.00 $230,000 13,722
2024-08-19 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 2,000 $227.05 $454,100 3,670
2024-08-15 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 9,071 $224.55 $2,036,882 31,289
2024-08-15 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 2,950 $223.62 $659,670 40,360
2024-08-15 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 2,979 $222.65 $663,273 43,310
2024-08-08 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 586 $225.00 $131,850 14,722
2024-08-07 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 414 $225.00 $93,150 15,308
2024-08-05 BERBERIAN LANCE EVP, CIO & CTO Open-market sell
S
 Common Stock 9,848 $228.95 $2,254,685 15,921
2024-08-05 BERBERIAN LANCE EVP, CIO & CTO Open-market sell
S
 Common Stock 2,245 $229.78 $515,867 25,769
2024-06-06 Rothman Paul Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 717 $0.00 $0 944
2024-06-06 Rothman Paul Dir Exercise / conversion
M
 Common Stock 717 — — 717
2024-05-14 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 200 $210.84 $42,167 5,637
2024-05-14 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 1,800 $210.83 $379,488 5,837
2024-05-02 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 250 $200.10 $50,025 15,722
2024-04-30 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 250 $204.13 $51,034 15,972
2024-04-29 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 2,439 $204.33 $498,358 2,087
2024-04-15 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Restricted Stock Unit 10,229 $0.00 $0 5,477
2024-04-15 EISENBERG GLENN A Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 4,496 $203.32 $914,127 40,556
2024-04-15 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 10,229 — — 45,052
2024-04-01 Schroeder Mark S EVP, Pres Diagnostics & COO Open-market sell
S
 Common Stock 6,477 $217.29 $1,407,387 5,036
2024-03-28 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 3,553 $216.74 $770,077 7,637
2024-03-27 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 6,158 — — 2,190
2024-03-27 van der Vaart Sandra D EVP, Chief Legal Officer Other disposed transaction
F
 Common Stock 2,605 $216.57 $564,165 11,190
2024-03-27 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M
 Common Stock 6,158 — — 13,795
2024-03-07 Schroeder Mark S EVP, Pres Diagnostics & COO Exercise / conversion
M · derivative
 Non-qualified Stock Options 2,119 $0.00 $0 0
2024-03-07 Schroeder Mark S EVP, Pres Diagnostics & COO Open-market sell
S
 Common Stock 5,048 $218.45 $1,102,736 5,036
2024-03-07 Schroeder Mark S EVP, Pres Diagnostics & COO Exercise / conversion
M
 Common Stock 2,119 $117.09 $248,114 10,084
2024-02-21 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Non-qualified Stock Options 14,054 $0.00 $0 0
2024-02-21 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 1,553 $217.98 $338,529 23,595
2024-02-21 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 6,665 $217.52 $1,449,774 25,148
2024-02-21 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 7,907 $215.68 $1,705,349 31,813
2024-02-21 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 18,379 $215.37 $3,958,214 39,720
2024-02-21 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 14,054 $163.63 $2,299,656 58,099
2024-02-13 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 237 $226.45 $53,669 7,637
2024-02-12 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 1,231 $227.45 $279,991 52,994
2024-02-11 Schechter Adam H President & CEO Exercise / conversion
M · derivative
 Restricted Stock Unit 2,964 $0.00 $0 95,277
2024-02-11 Schechter Adam H President & CEO Exercise / conversion
M
 Common Stock 2,964 — — 54,225
2024-02-08 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 259 $222.06 $57,514 7,637
2024-02-07 Schechter Adam H President & CEO Exercise / conversion
M · derivative
 Restricted Stock Unit 3,250 $0.00 $0 98,241
2024-02-07 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 1,149 $223.71 $257,043 51,261
2024-02-07 Schechter Adam H President & CEO Exercise / conversion
M
 Common Stock 3,250 — — 52,410
2024-02-06 Schechter Adam H President & CEO Equity grant / award
A · derivative
 Non-qualified Stock Options 41,400 $0.00 $0 41,400
2024-02-06 Schechter Adam H President & CEO Equity grant / award
A · derivative
 Restricted Stock Unit 13,380 $0.00 $0 101,491
2024-02-02 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 131 $0.00 $0 3,727
2024-02-02 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 45 $221.54 $9,969 2,173
2024-02-02 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 131 — — 2,218
2023-12-15 DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl Exercise / conversion
M · derivative
 Restricted Stock Unit 64 $0.00 $0 4,806
2023-12-15 DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl Other disposed transaction
F
 Common Stock 19 $219.50 $4,170 3,355
2023-12-15 DiVincenzo Jonathan P. EVP, Pres, Central Labs & Intl Exercise / conversion
M
 Common Stock 64 — — 3,374
2023-11-16 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 1,384 $210.71 $291,627 2,087
2023-10-12 Kliphouse Kirsten Marie Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 372 $0.00 $0 947
2023-10-12 Kliphouse Kirsten Marie Dir Exercise / conversion
M
 Common Stock 372 — — 372
2023-08-08 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 5,000 $211.57 $1,057,832 15,275
2023-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 56 $0.00 $0 3,858
2023-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 17 $213.61 $3,631 3,471
2023-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 56 — — 3,488
2023-06-30 van der Vaart Sandra D EVP, Chief Legal Officer Equity grant / award
A · derivative
 Restricted Stock Unit 6,207 $0.00 $0 7,974
2023-06-29 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 212 $240.00 $50,880 7,605
2023-06-20 LABORATORY CORP OF AMERICA HOLDINGS 10% Other disposed transaction
J
 Common Stock 100 $0.00 $0 0
2023-06-06 Rothman Paul Dir Equity grant / award
A · derivative
 Restricted Stock Unit 642 $0.00 $0 642
2023-05-19 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M · derivative
 Non-qualified Stock Options 4,300 $0.00 $0 0
2023-05-19 Kirchgraber Paul R CEO, Covance Drug Development Open-market sell
S
 Common Stock 4,300 $216.91 $932,707 12,946
2023-05-19 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M
 Common Stock 4,300 $182.51 $784,793 17,246
2023-05-18 Schroeder Mark S EVP, Pres Diagnostics & COO Exercise / conversion
M · derivative
 Non-qualified Stock Options 1,500 $0.00 $0 1,900
2023-05-18 Schroeder Mark S EVP, Pres Diagnostics & COO Open-market sell
S
 Common Stock 1,500 $216.77 $325,155 6,687
2023-05-18 Schroeder Mark S EVP, Pres Diagnostics & COO Exercise / conversion
M
 Common Stock 1,500 $130.60 $195,900 8,187
2023-05-05 Schroeder Mark S EVP, Pres Diagnostics & COO Equity grant / award
A · derivative
 Restricted Stock Unit 440 $0.00 $0 3,121
2023-05-05 Schroeder Mark S EVP, Pres Diagnostics & COO Equity grant / award
A · derivative
 Non-qualified Stock Options 1,400 $0.00 $0 1,400
2023-04-05 GRAHAM ANITA Z EVP, CHRO Equity grant / award
A · derivative
 Restricted Stock Unit 990 $0.00 $0 990
2023-04-05 GRAHAM ANITA Z EVP, CHRO Equity grant / award
A · derivative
 Non-qualified Stock Options 3,000 $0.00 $0 3,000
2023-03-30 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 18,646 $224.70 $4,189,756 46,888
2023-03-30 Schechter Adam H President & CEO Equity grant / award
A
 Common Stock 42,353 $0.00 $0 65,534
2023-03-02 Summy Amy B. EVP, Chief Marketing Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 1,340 $0.00 $0 1,180
2023-03-02 Summy Amy B. EVP, Chief Marketing Officer Other disposed transaction
F
 Common Stock 374 $239.46 $89,558 1,669
2023-03-02 Summy Amy B. EVP, Chief Marketing Officer Exercise / conversion
M
 Common Stock 1,340 — — 2,043
2023-02-21 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,000 $0.00 $0 4,300
2023-02-21 Kirchgraber Paul R CEO, Covance Drug Development Open-market sell
S
 Common Stock 8,000 $250.58 $2,004,675 9,069
2023-02-21 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M
 Common Stock 3,000 $182.51 $547,530 17,069
2023-02-14 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 309 $247.63 $76,518 6,687
2023-02-13 BELINGARD JEAN-LUC Dir Other disposed transaction
F
 Common Stock 75 $248.13 $18,610 16,929
2023-02-11 BELINGARD JEAN-LUC Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 742 $0.00 $0 849
2023-02-11 BELINGARD JEAN-LUC Dir Exercise / conversion
M
 Common Stock 742 — — 17,004
2023-02-07 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Non-qualified Stock Options 1,100 $0.00 $0 1,100
2023-02-07 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Restricted Stock Unit 360 $0.00 $0 857
2023-02-06 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 1,368 $244.50 $334,476 21,695
2023-02-04 Schechter Adam H President & CEO Exercise / conversion
M · derivative
 Restricted Stock Unit 3,507 $0.00 $0 10,744
2023-02-04 Schechter Adam H President & CEO Exercise / conversion
M
 Common Stock 3,507 — — 23,063
2023-02-02 Seltz Judith C EVP, CHRO Exercise / conversion
M · derivative
 Restricted Stock Unit 220 $0.00 $0 1,210
2023-02-02 Seltz Judith C EVP, CHRO Other disposed transaction
F
 Common Stock 77 $254.99 $19,634 1,602
2023-02-02 Seltz Judith C EVP, CHRO Exercise / conversion
M
 Common Stock 220 — — 1,679
2023-01-09 Pike Thomas Pres & CEO Clinical Business Equity grant / award
A · derivative
 Restricted Stock Unit 16,960 $0.00 $0 16,960
2022-11-08 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 1,116 $232.67 $259,660 6,687
2022-11-07 Schroeder Mark S EVP, President-Diagnostics Lab Other disposed transaction
F
 Common Stock 894 $233.77 $208,990 7,803
2022-11-05 Schroeder Mark S EVP, President-Diagnostics Lab Exercise / conversion
M · derivative
 Restricted Stock Unit 2,010 $0.00 $0 2,717
2022-11-05 Schroeder Mark S EVP, President-Diagnostics Lab Exercise / conversion
M
 Common Stock 2,010 — — 8,697
2022-11-01 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Restricted Stock Unit 12,032 $0.00 $0 13,844
2022-11-01 EISENBERG GLENN A Chief Financial Officer, EVP Equity grant / award
A · derivative
 Restricted Stock Unit 9,170 $0.00 $0 25,876
2022-11-01 EISENBERG GLENN A Chief Financial Officer, EVP Equity grant / award
A · derivative
 Performance Share Unit 9,170 $0.00 $0 9,170
2022-11-01 EISENBERG GLENN A Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 5,348 $222.56 $1,190,251 33,842
2022-11-01 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 12,032 — — 39,190
2022-10-12 Kliphouse Kirsten Marie Dir Equity grant / award
A · derivative
 Restricted Stock Unit 333 $0.00 $0 333
2022-09-26 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 2,830 $211.86 $599,573 27,158
2022-09-26 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 11,699 $211.13 $2,470,064 29,988
2022-09-26 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 4,844 $210.21 $1,018,242 41,687
2022-09-26 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 5,627 $209.29 $1,177,697 46,531
2022-09-07 Caveney Brian J EVP, President of Diagnostics Open-market buy
P
 Common Stock 44 $231.20 $10,251 14,282
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Non-qualified Stock Options 11,600 $0.00 $0 0
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Non-qualified Stock Options 9,100 $0.00 $0 0
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Non-qualified Stock Options 11,400 $0.00 $0 0
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 1,500 $254.88 $382,318 52,158
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 19,338 $254.26 $4,916,861 53,658
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 11,262 $253.26 $2,852,270 72,996
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 11,600 $146.59 $1,700,444 84,258
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 9,100 $168.49 $1,533,259 72,658
2022-08-03 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 11,400 $130.60 $1,488,840 63,558
2022-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
G
 Common Stock 351 $0.00 $0 1,993
2022-06-07 Caveney Brian J EVP, President of Diagnostics Open-market buy
P
 Common Stock 42 $242.19 $10,174 14,172
2022-03-29 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 2,356 $277.11 $652,871 6,605
2022-03-28 BERBERIAN LANCE EVP, CIO & CTO Other disposed transaction
F
 Common Stock 2,360 $276.42 $652,351 19,502
2022-03-27 BERBERIAN LANCE EVP, CIO & CTO Equity grant / award
A
 Common Stock 5,310 $0.00 $0 21,862
2022-03-25 Wengel Kathryn E Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 603 $0.00 $0 742
2022-03-25 Wengel Kathryn E Dir Exercise / conversion
M
 Common Stock 603 — — 603
2022-03-10 Summy Amy B. EVP, Chief Marketing Officer Open-market sell
S
 Common Stock 249 $262.21 $65,290 250
2022-02-16 NEUPERT PETER M Dir Open-market buy
P
 Common Stock 600 $264.57 $158,742 10,254
2022-02-16 NEUPERT PETER M Dir Open-market buy
P
 Common Stock 1,600 $263.98 $422,368 9,654
2022-02-16 NEUPERT PETER M Dir Open-market buy
P
 Common Stock 1,300 $262.85 $341,705 8,054
2022-02-15 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 207 $273.98 $56,714 6,605
2022-02-14 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 200 $272.68 $54,536 1,789
2022-02-14 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 61 $272.68 $16,633 1,989
2022-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 680 $0.00 $0 814
2022-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 187 $0.00 $0 1,494
2022-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 680 — — 2,050
2022-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 187 — — 1,370
2022-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Non-qualified Stock Options 1,100 $0.00 $0 1,100
2022-02-11 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Restricted Stock Unit 330 $0.00 $0 1,681
2022-02-11 Williams R Sanders Dir Equity grant / award
A · derivative
 Restricted Stock Unit 742 $0.00 $0 742
2022-02-04 BERBERIAN LANCE EVP, CIO & CTO Exercise / conversion
M · derivative
 Restricted Stock Unit 373 $0.00 $0 3,676
2022-02-04 BERBERIAN LANCE EVP, CIO & CTO Other disposed transaction
F
 Common Stock 109 $277.48 $30,245 14,643
2022-02-04 BERBERIAN LANCE EVP, CIO & CTO Exercise / conversion
M
 Common Stock 373 — — 14,752
2022-02-02 NEUPERT PETER M Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 771 $0.00 $0 0
2022-02-02 NEUPERT PETER M Dir Exercise / conversion
M
 Common Stock 771 — — 6,754
2021-12-15 Gilliland Dwight Gary Dir Open-market sell
S
 Common Stock 18 $302.31 $5,442 6,252
2021-12-15 Gilliland Dwight Gary Dir Open-market sell
S
 Common Stock 25 $302.28 $7,557 6,270
2021-12-15 Gilliland Dwight Gary Dir Open-market sell
S
 Common Stock 100 $302.26 $30,226 6,295
2021-12-15 Gilliland Dwight Gary Dir Open-market sell
S
 Common Stock 357 $302.25 $107,903 6,395
2021-11-05 Caveney Brian J EVP, President of Diagnostics Exercise / conversion
M · derivative
 Restricted Stock Unit 2,010 $0.00 $0 7,098
2021-11-05 Caveney Brian J EVP, President of Diagnostics Other disposed transaction
F
 Common Stock 899 $274.84 $247,081 9,182
2021-11-05 Caveney Brian J EVP, President of Diagnostics Exercise / conversion
M
 Common Stock 2,010 — — 10,081
2021-11-01 Schechter Adam H President & CEO Exercise / conversion
M · derivative
 Restricted Stock Unit 2,007 $0.00 $0 17,341
2021-11-01 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 886 $288.78 $255,859 12,409
2021-11-01 Schechter Adam H President & CEO Exercise / conversion
M
 Common Stock 2,007 — — 13,295
2021-09-15 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 4,500 $0.00 $0 0
2021-09-15 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 4,500 $296.78 $1,335,510 5,265
2021-09-15 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M
 Common Stock 4,500 $84.86 $381,870 9,765
2021-08-02 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 15 $297.61 $4,464 1,011
2021-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 50 $0.00 $0 1,617
2021-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 50 — — 1,026
2021-06-07 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 4,500 $0.00 $0 4,500
2021-06-07 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 4,500 $266.56 $1,199,520 5,237
2021-06-07 van der Vaart Sandra D EVP, Chief Legal Officer Exercise / conversion
M
 Common Stock 4,500 $84.86 $381,870 9,737
2021-05-06 Kirchgraber Paul R CEO, Covance Drug Development Open-market sell
S
 Common Stock 2,500 $276.55 $691,375 7,844
2021-05-03 BELINGARD JEAN-LUC Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 2,600 $0.00 $0 0
2021-05-03 BELINGARD JEAN-LUC Dir Open-market sell
S
 Common Stock 2,600 $269.16 $699,803 15,569
2021-05-03 BELINGARD JEAN-LUC Dir Exercise / conversion
M
 Common Stock 2,600 $98.49 $256,074 18,169
2021-04-03 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M · derivative
 Restricted Stock Unit 1,010 $0.00 $0 6,781
2021-04-03 Kirchgraber Paul R CEO, Covance Drug Development Other disposed transaction
F
 Common Stock 452 $252.67 $114,207 10,344
2021-04-03 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M
 Common Stock 1,010 — — 10,796
2021-03-30 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 667 $251.88 $168,004 5,006
2021-03-27 EISENBERG GLENN A Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 3,595 $251.58 $904,430 37,433
2021-03-27 EISENBERG GLENN A Chief Financial Officer, EVP Equity grant / award
A
 Common Stock 8,042 $0.00 $0 41,028
2021-03-25 Wengel Kathryn E Dir Equity grant / award
A · derivative
 Restricted Stock Unit 603 $0.00 $0 603
2021-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 633 $0.00 $0 1,267
2021-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 1,533 $0.00 $0 767
2021-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 633 $182.51 $115,529 976
2021-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 2,317 $241.51 $559,589 343
2021-02-18 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 1,533 $146.59 $224,722 2,660
2021-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 680 $0.00 $0 1,667
2021-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 187 $0.00 $0 2,347
2021-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 201 $238.26 $47,890 1,127
2021-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 680 — — 1,328
2021-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Other disposed transaction
F
 Common Stock 62 $238.26 $14,772 648
2021-02-12 Wilkinson Peter J SVP, Chief Accounting Officer Exercise / conversion
M
 Common Stock 187 — — 710
2021-02-04 Schechter Adam H President & CEO Exercise / conversion
M · derivative
 Restricted Stock Unit 3,506 $0.00 $0 19,348
2021-02-04 Schechter Adam H President & CEO Other disposed transaction
F
 Common Stock 1,028 $223.78 $230,046 11,288
2021-02-04 Schechter Adam H President & CEO Exercise / conversion
M
 Common Stock 3,506 — — 12,316
2021-02-02 Kong Garheng Dir Equity grant / award
A · derivative
 Restricted Stock Unit 771 $0.00 $0 1,757
2021-01-26 Williams R Sanders Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 1,300 $0.00 $0 0
2021-01-26 Williams R Sanders Dir Exercise / conversion
M
 Common Stock 1,300 $98.49 $128,037 5,246
2020-12-01 Davis Jeffrey A. Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 173 $0.00 $0 986
2020-12-01 Davis Jeffrey A. Dir Exercise / conversion
M
 Common Stock 173 — — 173
2020-11-06 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 588 $214.59 $126,179 3,949
2020-11-05 Caveney Brian J EVP, President of Diagnostics Exercise / conversion
M · derivative
 Restricted Stock Unit 2,010 $0.00 $0 11,208
2020-11-05 Caveney Brian J EVP, President of Diagnostics Other disposed transaction
F
 Common Stock 886 $214.42 $189,976 4,221
2020-11-05 Caveney Brian J EVP, President of Diagnostics Exercise / conversion
M
 Common Stock 2,010 — — 5,107
2020-11-04 Kirchgraber Paul R CEO, Covance Drug Development Open-market sell
S
 Common Stock 1,500 $214.14 $321,204 7,698
2020-11-02 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Restricted Stock Unit 9,024 $0.00 $0 26,626
2020-11-02 EISENBERG GLENN A Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 4,034 $207.23 $835,966 31,114
2020-11-02 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 9,024 — — 35,148
2020-09-25 Caveney Brian J EVP, President of Diagnostics Exercise / conversion
M · derivative
 Restricted Stock Unit 970 $0.00 $0 13,218
2020-09-25 Caveney Brian J EVP, President of Diagnostics Other disposed transaction
F
 Common Stock 289 $180.99 $52,306 3,097
2020-09-25 Caveney Brian J EVP, President of Diagnostics Exercise / conversion
M
 Common Stock 970 — — 3,386
2020-09-21 Williams R Sanders Dir Equity grant / award
G
 Common Stock 1,149 $0.00 $0 3,946
2020-08-01 Wilkinson Peter J SVP, Chief Accounting Officer Equity grant / award
A · derivative
 Restricted Stock Unit 150 $0.00 $0 2,334
2020-07-08 Williams R Sanders Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 1,300 $0.00 $0 1,300
2020-07-08 Williams R Sanders Dir Open-market sell
S
 Common Stock 1,300 $173.12 $225,056 5,095
2020-07-08 Williams R Sanders Dir Exercise / conversion
M
 Common Stock 1,300 $98.49 $128,037 6,395
2020-07-02 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 435 $170.00 $73,950 4,044
2020-06-24 van der Vaart Sandra D EVP, Chief Legal Officer Open-market sell
S
 Common Stock 436 $160.33 $69,904 4,479
2020-05-05 KING DAVID P Dir Open-market sell
S
 Common Stock 31,250 $160.00 $5,000,000 312,554
2020-04-03 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M · derivative
 Restricted Stock Unit 1,010 $0.00 $0 9,608
2020-04-03 Kirchgraber Paul R CEO, Covance Drug Development Other disposed transaction
F
 Common Stock 372 $113.31 $42,151 8,087
2020-04-03 Kirchgraber Paul R CEO, Covance Drug Development Exercise / conversion
M
 Common Stock 1,010 $0.00 $0 8,459
2020-03-30 KING DAVID P Dir Other disposed transaction
F
 Common Stock 24,583 $131.95 $3,243,727 343,804
2020-03-30 KING DAVID P Dir Equity grant / award
A
 Common Stock 54,995 $0.00 $0 368,387
2020-03-10 Seltz Judith C EVP, CHRO Open-market buy
P
 Common Stock 330 $168.56 $55,625 580
2020-03-02 Summy Amy B. EVP, Chief Marketing Officer Equity grant / award
A · derivative
 Non-qualified Stock Options 3,600 $0.00 $0 3,600
2020-03-02 Summy Amy B. EVP, Chief Marketing Officer Equity grant / award
A · derivative
 Restricted Stock Unit 1,340 $0.00 $0 2,140
2020-03-02 Summy Amy B. EVP, Chief Marketing Officer Equity grant / award
A · derivative
 Restricted Stock Unit 800 $0.00 $0 800
2020-02-28 Seltz Judith C EVP, CHRO Open-market buy
P
 Common Stock 250 $174.94 $43,735 250
2020-02-21 Wilkinson Peter J SVP, Chief Accounting Officer Open-market sell
S
 Common Stock 297 $189.65 $56,326 297
2020-02-19 BELINGARD JEAN-LUC Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,100 $0.00 $0 0
2020-02-19 BELINGARD JEAN-LUC Dir Open-market sell
S
 Common Stock 26,479 $189.76 $5,024,750 14,682
2020-02-19 BELINGARD JEAN-LUC Dir Exercise / conversion
M
 Common Stock 3,100 $77.19 $239,289 41,161
2020-02-12 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Restricted Stock Unit 940 $0.00 $0 35,650
2020-02-12 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M · derivative
 Restricted Stock Unit 780 $0.00 $0 36,590
2020-02-12 EISENBERG GLENN A Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 280 $187.51 $52,503 18,966
2020-02-12 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 940 — — 19,246
2020-02-12 EISENBERG GLENN A Chief Financial Officer, EVP Other disposed transaction
F
 Common Stock 232 $187.51 $43,502 18,306
2020-02-12 EISENBERG GLENN A Chief Financial Officer, EVP Exercise / conversion
M
 Common Stock 780 — — 18,538
2020-02-10 Schroeder Mark S EVP, President-Diagnostics Lab Open-market sell
S
 Common Stock 108 $181.99 $19,655 300
2020-02-07 Schroeder Mark S EVP, President-Diagnostics Lab Exercise / conversion
M · derivative
 Restricted Stock Unit 297 $0.00 $0 9,027
2020-02-07 Schroeder Mark S EVP, President-Diagnostics Lab Other disposed transaction
F
 Common Stock 82 $182.33 $14,951 408
2020-02-07 Schroeder Mark S EVP, President-Diagnostics Lab Exercise / conversion
M
 Common Stock 297 — — 490
2020-02-04 Kong Garheng Dir Equity grant / award
A · derivative
 Restricted Stock Unit 986 $0.00 $0 2,213
2020-02-04 van der Vaart Sandra D SVP, Global General Counsel Equity grant / award
A · derivative
 Non-qualified Stock Options 3,900 $0.00 $0 3,900
2020-02-04 van der Vaart Sandra D SVP, Global General Counsel Equity grant / award
A · derivative
 Restricted Stock Unit 900 $0.00 $0 2,697
2020-01-01 KING DAVID P Dir Equity grant / award
A · derivative
 Restricted Stock Unit 38,570 $0.00 $0 62,527
2019-12-04 BELINGARD JEAN-LUC Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 3,271 $0.00 $0 1,227
2019-12-04 BELINGARD JEAN-LUC Dir Other disposed transaction
F
 Common Stock 327 $171.82 $56,185 36,957
2019-12-04 BELINGARD JEAN-LUC Dir Exercise / conversion
M
 Common Stock 3,271 — — 37,284
2019-12-01 Davis Jeffrey A. Dir Equity grant / award
A · derivative
 Restricted Stock Unit 173 $0.00 $0 173
2019-11-05 Caveney Brian J EVP, President of Diagnostics Equity grant / award
A · derivative
 Restricted Stock Unit 6,030 $0.00 $0 15,377
2019-11-01 Kirchgraber Paul R CEO, Covance Drug Development Equity grant / award
A · derivative
 Restricted Stock Unit 6,020 $0.00 $0 9,854
2019-10-28 KING DAVID P President & CEO Open-market sell
S
 Common Stock 12,352 $166.21 $2,053,053 305,933
2019-10-28 KING DAVID P President & CEO Open-market sell
S
 Common Stock 10,391 $165.32 $1,717,832 318,285
2019-10-28 KING DAVID P President & CEO Open-market sell
S
 Common Stock 7,434 $164.16 $1,220,332 328,676
2019-09-23 ANDERSON KERRII B Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 2,600 $0.00 $0 0
2019-09-23 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 2,600 $171.85 $446,810 17,933
2019-09-23 ANDERSON KERRII B Dir Exercise / conversion
M
 Common Stock 2,600 $98.49 $256,074 20,533
2019-09-04 Uthgenannt Lisa J Chief Human Resources Officer Exercise / conversion
M · derivative
 Non-qualified Stock Options 2,466 $0.00 $0 1,234
2019-09-04 Uthgenannt Lisa J Chief Human Resources Officer Open-market sell
S
 Common Stock 2,466 $168.59 $415,743 4,660
2019-09-04 Uthgenannt Lisa J Chief Human Resources Officer Exercise / conversion
M
 Common Stock 2,466 $130.60 $322,060 7,126
2019-08-30 BERBERIAN LANCE SVP, Chief Information Officer Open-market sell
S
 Common Stock 5,902 $169.80 $1,002,172 6,097
2019-08-05 Williams R Sanders Dir Open-market sell
S
 Common Stock 500 $162.91 $81,455 6,886
2019-07-08 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 5,563 $176.75 $983,260 17,059
2019-06-20 ANDERSON KERRII B Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,100 $0.00 $0 0
2019-06-20 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 3,100 $170.00 $527,000 19,133
2019-06-20 ANDERSON KERRII B Dir Exercise / conversion
M
 Common Stock 3,100 $77.19 $239,289 22,233
2019-06-07 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 1,294 $168.41 $217,921 22,622
2019-06-07 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 4,450 $167.65 $746,045 23,916
2019-06-07 EISENBERG GLENN A Chief Financial Officer, EVP Open-market sell
S
 Common Stock 4,256 $166.82 $710,003 28,366
2019-05-09 MITTELSTAEDT ROBERT E JR Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 306 $0.00 $0 0
2019-05-09 MITTELSTAEDT ROBERT E JR Dir Exercise / conversion
M
 Common Stock 306 — — 15,515
2019-05-06 Williams R Sanders Dir Open-market sell
S
 Common Stock 500 $162.20 $81,100 7,386
2019-05-03 MITTELSTAEDT ROBERT E JR Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,700 $0.00 $0 0
2019-05-03 MITTELSTAEDT ROBERT E JR Dir Open-market sell
S
 Common Stock 3,700 $166.30 $615,310 15,209
2019-05-03 MITTELSTAEDT ROBERT E JR Dir Exercise / conversion
M
 Common Stock 3,700 $64.42 $238,354 18,909
2019-05-02 Uthgenannt Lisa J Chief Human Resources Officer Open-market sell
S
 Common Stock 4,000 $164.00 $656,000 4,638
2019-04-03 Ratliff John D CEO, Covance Drug Development Exercise / conversion
M · derivative
 Restricted Stock Unit 2,424 $0.00 $0 19,787
2019-04-03 Ratliff John D CEO, Covance Drug Development Other disposed transaction
F
 Common Stock 1,084 $156.68 $169,841 16,941
2019-04-03 Ratliff John D CEO, Covance Drug Development Exercise / conversion
M
 Common Stock 2,424 — — 18,025
2019-04-01 KING DAVID P President & CEO Other disposed transaction
F
 Common Stock 41,311 $154.79 $6,394,530 297,387
2019-04-01 KING DAVID P President & CEO Equity grant / award
A
 Common Stock 92,417 $0.00 $0 338,698
2019-02-12 Schechter Adam H Dir Equity grant / award
A · derivative
 Restricted Stock Unit 1,227 $0.00 $0 1,227
2019-02-12 Schechter Adam H Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 1,038 $0.00 $0 0
2019-02-12 Schechter Adam H Dir Exercise / conversion
M
 Common Stock 1,038 — — 6,462
2019-02-12 BELINGARD JEAN-LUC Dir Equity grant / award
A · derivative
 Restricted Stock Unit 1,227 $0.00 $0 4,506
2019-02-12 BELINGARD JEAN-LUC Dir Exercise / conversion
M · derivative
 Restricted Stock Unit 1,038 $0.00 $0 3,279
2019-02-12 BELINGARD JEAN-LUC Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,700 $0.00 $0 0
2019-02-12 BELINGARD JEAN-LUC Dir Other disposed transaction
F
 Common Stock 104 $146.59 $15,245 34,013
2019-02-12 BELINGARD JEAN-LUC Dir Exercise / conversion
M
 Common Stock 1,038 — — 34,117
2019-02-12 BELINGARD JEAN-LUC Dir Open-market sell
S
 Common Stock 3,700 $146.06 $540,407 33,079
2019-02-12 BELINGARD JEAN-LUC Dir Exercise / conversion
M
 Common Stock 3,700 $64.42 $238,354 36,779
2019-02-11 Uthgenannt Lisa J Chief Human Resources Officer Exercise / conversion
M · derivative
 Restricted Stock Unit 604 $0.00 $0 1,097
2019-02-11 Uthgenannt Lisa J Chief Human Resources Officer Other disposed transaction
F
 Common Stock 240 $144.29 $34,630 4,336
2019-02-11 Uthgenannt Lisa J Chief Human Resources Officer Exercise / conversion
M
 Common Stock 604 — — 4,576
2019-02-07 Ratliff John D CEO, Covance Drug Development Exercise / conversion
M · derivative
 Restricted Stock Unit 1,863 $0.00 $0 24,474
2019-02-07 Ratliff John D CEO, Covance Drug Development Other disposed transaction
F
 Common Stock 556 $147.46 $81,988 10,665
2019-02-07 Ratliff John D CEO, Covance Drug Development Exercise / conversion
M
 Common Stock 1,863 — — 11,261
2018-12-04 BELINGARD JEAN-LUC Dir Equity grant / award
A · derivative
 Restricted Stock Unit 3,174 $0.00 $0 4,212
2018-11-27 Williams R Sanders Dir Open-market sell
S
 Common Stock 350 $162.14 $56,749 7,886
2018-11-19 Schechter Adam H Dir Equity grant / award
G
 Common Stock 610 $0.00 $0 5,424
2018-11-05 ANDERSON KERRII B Dir Exercise / conversion
M · derivative
 Non-qualified Stock Options 3,700 $0.00 $0 0
2018-11-05 ANDERSON KERRII B Dir Open-market sell
S
 Common Stock 3,700 $163.29 $604,162 18,095
2018-11-05 ANDERSON KERRII B Dir Exercise / conversion
M
 Common Stock 3,700 $64.42 $238,354 21,795

Regulatory Activity

Last 12 months to 2025-04-29
Insider Filings (Forms 3/4/5) — 12 months
25
Material Event Filings (8-K) — 12 months
23

8-K Material Event Filing Activity

Monthly count

Insider Trading Activity (Forms 3/4/5)

Monthly count
For informational purposes only — not guaranteed to be accurate or complete.